Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of rabbit
anti-thymocyte globulin (Thymoglobulin®), sirolimus (Rapamune®), and mycophenolate mofetil
(Cellcept®) can help to prevent graft versus host disease (GVHD). The safety of this drug
combination will also be studied.
Primary Objective: To determine efficacy and toxicity of a regimen of thymoglobulin,
sirolimus and mycophenolate mofetil for prevention of acute GVHD after allogeneic stem cell
transplantation from human leukocyte antigen (HLA) identical related or unrelated donors.
Secondary Objective: To assess engraftment, chronic GVHD, relapse and survival.